Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Conversion therapy of stage IVb unresectable gallbladder carcinoma.

Literature DB >> 35464281

Conversion therapy of stage IVb unresectable gallbladder carcinoma.

Cong Ning¹, Xinmu Zhang², Xiaobo Yang¹, Xinting Sang¹, Haitao Zhao¹, Hanping Wang².

Abstract

Entities: Chemical

Year: 2022 PMID： 35464281 PMCID： PMC9023841 DOI： 10.21037/hbsn-22-78

Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN： 2304-3881 Impact factor: 7.293

Keyword Cloud
References

× No keyword cloud information.

10 in total

1. Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?

Authors: Anton J Bilchik; J Randolph Hecht
Journal: J Clin Oncol Date: 2008-04-10 Impact factor: 44.544

Review 2. The place of downstaging for hepatocellular carcinoma.

Authors: Christian Toso; Gilles Mentha; Norman M Kneteman; Pietro Majno
Journal: J Hepatol Date: 2010-03-15 Impact factor: 25.083

3. Nutritional support treatment for perioperative patients in hepatobiliary surgery.

Authors: Shuifang Jin; Ronglin Jiang; Xi Xing; Weibin Ma
Journal: Hepatobiliary Surg Nutr Date: 2020-06 Impact factor: 7.293

Review 4. Modern therapeutic approaches for the treatment of malignant liver tumours.

Authors: Henrik Petrowsky; Ralph Fritsch; Matthias Guckenberger; Michelle L De Oliveira; Philipp Dutkowski; Pierre-Alain Clavien
Journal: Nat Rev Gastroenterol Hepatol Date: 2020-07-17 Impact factor: 46.802

5. Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapy.

Authors: Xiaobo Yang; Haifeng Xu; Bangyou Zuo; Xu Yang; Jin Bian; Junyu Long; Dongxu Wang; Junwei Zhang; Cong Ning; Yanyu Wang; Ziyu Xun; Yunchao Wang; Xin Lu; Yilei Mao; Xinting Sang; Haitao Zhao
Journal: Hepatobiliary Surg Nutr Date: 2021-08 Impact factor: 7.293

6. Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma.

Authors: Jianzhen Lin; Xu Yang; Junyu Long; Songhui Zhao; Jinzhu Mao; Dongxu Wang; Yi Bai; Jin Bian; Lei Zhang; Xiaobo Yang; Anqiang Wang; Fucun Xie; Weiwei Shi; Huayu Yang; Jie Pan; Ke Hu; Mei Guan; Lin Zhao; Li Huo; Yilei Mao; Xinting Sang; Kai Wang; Haitao Zhao
Journal: Hepatobiliary Surg Nutr Date: 2020-08 Impact factor: 7.293